Comparative Pharmacology
Head-to-head clinical analysis: CYSVIEW KIT versus LYMPHAZURIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSVIEW KIT versus LYMPHAZURIN.
CYSVIEW KIT vs LYMPHAZURIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholic acid is a primary bile acid that acts as a choleretic and bile acid replacement therapy. It competitively inhibits hepatic bile acid synthesis via negative feedback on cholesterol 7α-hydroxylase (CYP7A1), reducing the production of toxic bile acid intermediates in patients with inborn errors of bile acid synthesis.
Lymphazurin is a diagnostic dye composed of isosulfan blue. It is a hydrophilic molecule that selectively binds to serum albumin and is preferentially taken up by lymphatic vessels. When injected subcutaneously or intradermally, it enters the lymphatic system and stains the lymphatic vessels and nodes, allowing for visual identification during lymph node mapping and sentinel lymph node biopsy procedures.
Intravenous: 5 mg/kg as a single dose administered over 30 minutes.
0.1 mL (100 mcg) administered via submucosal injection in 3 divided doses into the distal submucosa surrounding the cervical os (12, 4, and 8 o'clock positions) at a depth of 3 mm, 10 minutes prior to the procedure.
None Documented
None Documented
Terminal elimination half-life: 1.9-2.5 hours (mean 2.1 h) in normal renal function; prolonged in renal impairment (up to 20 h in ESRD).
Terminal elimination half-life is 18–24 hours; prolonged in renal impairment (up to 40 hours in severe impairment), requiring dose adjustment.
Renal: 90% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal excretion as unchanged drug (approximately 70%) and as glucuronide conjugate (20%); negligible biliary or fecal elimination (<5%).
Category C
Category C
Diagnostic Dye
Diagnostic Dye